Also compare CPTCQ's financing arrangements (bad) vs BIPH's (good). If Biophan's "deal" and equity investment with BSX gets delayed further, they at least have a financing agreement with SBI to fall back on...for $30 million with trenches between $2 and $4 per share. That sort of confidence in BIPH by a respected financier is encouraging and should put a cap in any potential decline in share price ($2, imo)...but, I agree with E-P, I think this "deal" is done, just not yet announced. Nearly 2 years of a joint developement agreement, all Weiner's comments of late, etc-no way it ain't gettin' done very, very "soon."
